Digital health technology company Huma Therapeutics has partnered with AstraZeneca to accelerate innovation for digital-first patient care.

The partnership follows previous use cases between Huma and AstraZeneca to improve healthcare outcomes by bridging the gap between patients and physicians through digital health solutions.

Under the agreement, Huma acquired AstraZeneca’s digital health platform AMAZE and AstraZeneca becomes a shareholder of Huma.

Together, the companies will launch software as a Medical Device (SaMD) companion apps to target several therapeutic areas and help expedite the adoption of decentralised clinical trials.

The apps will be built on Huma’s technologies powering digital-first care for over 1.8 million active patient users across more than 3,000 hospitals and clinics.

Huma CEO Dan Vahdat said: “Our track record of scaling innovation has set the stage for this important partnership with one of the world’s largest biopharmaceutical companies.

“I am excited to have AstraZeneca’s support to build upon our 10-year experience of delivering digital-first solutions across healthcare and clinical trials.

“The combination of pioneering leadership, global-reach, deep medical knowledge and digital innovation will enable our award-winning1 platform to help more people live longer, fuller lives.”

AstraZeneca has developed the AMAZE chronic disease management platform to enhance the care of patients. The alliance with Huma will use AMAZE’s early achievements to drive digital-first care across therapeutic areas and introduce SaMDs.

AstraZeneca chief commercial digital officer Karan Arora said: “This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space as well as in the industry for chronic diseases and SaMDs in support of different treatments.

“With Huma, we are accelerating AstraZeneca’s ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives.”